VanEck Biotech ETF
BBH
105 hedge funds and large institutions have $136M invested in VanEck Biotech ETF in 2021 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 30 increasing their positions, 26 reducing their positions, and 9 closing their positions.
285% more call options, than puts
Call options by funds: $1.37M | Put options by funds: $355K
15% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 26
11% more capital invested
Capital invested by funds: $123M → $136M (+$13.4M)
2.41% more ownership
Funds ownership: 25.65% → 28.06% (+2.4%)
0% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 9
3% less funds holding
Funds holding: 108 → 105 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$9.04M |
| 2 |
FP
Financial Perspectives
Minneapolis,
Minnesota
|
+$2.78M |
| 3 |
FFN
Focus Financial Network
Minneapolis,
Minnesota
|
+$2.52M |
| 4 |
HighTower Advisors
Chicago,
Illinois
|
+$1.91M |
| 5 |
GT
Glenview Trust
Louisville,
Kentucky
|
+$1.68M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1.8M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.34M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$976K |
| 4 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$720K |
| 5 |
HPCM
Hunter Perkins Capital Management
Lombard,
Illinois
|
-$556K |
BBH Hedge Fund Activity: Q1 2021 in Review
105 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in VanEck Biotech ETF (BBH) for Q1 2021, worth a combined $136M — up 11% from $123M a quarter earlier.
Fund positioning in BBH was balanced in Q1 2021: 9 funds opened new positions, 9 closed out, 30 added to existing stakes and 26 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $9.04M. The largest seller was Royal Bank of Canada, cutting an estimated $1.8M.
- 105 institutional investors held VanEck Biotech ETF (BBH) as of Q1 2021, down from 108 in Q4 2020.
- Funds reported $136M of VanEck Biotech ETF stock for Q1 2021, up 11% quarter-over-quarter.
- 9 funds opened new VanEck Biotech ETF positions in Q1 2021 and 9 closed out, a net change of 0 holders.
- The largest VanEck Biotech ETF buyer in Q1 2021 was Goldman Sachs, an estimated $9.04M added.
- The largest VanEck Biotech ETF seller in Q1 2021 was Royal Bank of Canada, an estimated $1.8M sold.
Based on aggregated 13F filings for Q1 2021.